Resource and Technical AdvanceIn-Press PreviewClinical ResearchHematologyOncology
Open Access |
10.1172/jci.insight.209042
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by
Lee, S.
in:
PubMed
|
Google Scholar
|
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by
Cutler, C.
in:
PubMed
|
Google Scholar
|
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Ma, N. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by
Randolph, T.
in:
PubMed
|
Google Scholar
|
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Chen, G. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Pidala, J. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Hamilton, B. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Kitko, C. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Arai, S. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by El Jurdi, N. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Onstad, L. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Koyama, M. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Lee, C. in: PubMed | Google Scholar
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by
Paczesny, S.
in:
PubMed
|
Google Scholar
|
1Fred Hutchinson Cancer Center, Seattle, United States of America
2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America
3The University of Texas MD Anderson Cancer Center, Houston, United States of America
4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
6Vanderbilt University Medical Center, Nashville, United States of America
7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America
8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America
9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America
Find articles by Hill, G. in: PubMed | Google Scholar
Published July 28, 2026 - More info
BACKGROUND. Prior studies identified plasma proteins associated with chronic graft-versus-host disease (cGVHD). The goal of this cross-sectional study was to evaluate whether plasma biomarkers were associated with specific organ manifestations to help guide treatment choice.
METHODS. Plasma proteins were measured in patients with cGVHD (n = 695) from Chronic GVHD Consortium studies. Correlations of plasma protein levels with individual organ involvement were tested with p≤0.05 considered significant after Benjamini-Hochberg adjustment and adjustment for five baseline clinical variables.
RESULTS. Median time from cGVHD diagnosis to blood draw was 0.9 months (IQR 0.1–9.5). Donors were 50% HLA-matched unrelated, 32% matched related and the remainder were umbilical cord blood, haploidentical or mismatched unrelated donors. Methotrexate and calcineurin inhibitor acute GVHD (aGVHD) prophylaxis was used in 53% of patients. Overall, 326 (47%) had moderate and 244 (35%) had severe cGVHD with the following organ involvement at time of blood draw: skin (67%), mouth (60%), eye (49%), joint (34%), GI (31%), lung (23%), and liver (17%). After adjustment for batch effects and patient and transplant characteristics, fourteen plasma proteins were associated with organ involvement with independent AUCs of 0.7-0.8. All organs except eye were associated with at least one biomarker. However, no combination of plasma proteins improved model fit after adjusting for patient and transplant clinical variables.
CONCLUSION. Correlations between plasma proteins and organ involvement were identified but are not actionable. Our future investigations will focus on more granular and immediately proximal determinants of cGVHD biology in both blood and tissue.